M. Ramírez, Gustavo Peniche, J. Rodríguez, Carlos Nuño-Langre, E. Muciño-Ortega, J. Mould-Quevedo
{"title":"墨西哥转移性肾细胞癌患者舒尼替尼、贝伐单抗+干扰素和干扰素不良事件的经济分析","authors":"M. Ramírez, Gustavo Peniche, J. Rodríguez, Carlos Nuño-Langre, E. Muciño-Ortega, J. Mould-Quevedo","doi":"10.1007/BF03320883","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":101511,"journal":{"name":"PharmacoEconomics Spanish Research Articles","volume":"16 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2012-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Análisis económico de acontecimientos adversos producidos por sunitinib, bevacizumab + interferón alfa e interferón alfa en pacientes con carcinoma de células renales metastásico en México\",\"authors\":\"M. Ramírez, Gustavo Peniche, J. Rodríguez, Carlos Nuño-Langre, E. Muciño-Ortega, J. Mould-Quevedo\",\"doi\":\"10.1007/BF03320883\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":101511,\"journal\":{\"name\":\"PharmacoEconomics Spanish Research Articles\",\"volume\":\"16 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"PharmacoEconomics Spanish Research Articles\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/BF03320883\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"PharmacoEconomics Spanish Research Articles","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/BF03320883","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Análisis económico de acontecimientos adversos producidos por sunitinib, bevacizumab + interferón alfa e interferón alfa en pacientes con carcinoma de células renales metastásico en México